BIOMAT Database Logo BIOMAT Database Logo

Deferoxamine use in aluminum toxicity. 1986

M Lewis, and S Lesniak

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001927 Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. Intracranial Central Nervous System Disorders,Brain Disorders,CNS Disorders, Intracranial,Central Nervous System Disorders, Intracranial,Central Nervous System Intracranial Disorders,Encephalon Diseases,Encephalopathy,Intracranial CNS Disorders,Brain Disease,Brain Disorder,CNS Disorder, Intracranial,Encephalon Disease,Encephalopathies,Intracranial CNS Disorder
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000535 Aluminum A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98. Aluminium,Aluminium-27,Aluminum-27,Aluminium 27,Aluminum 27

Related Publications

M Lewis, and S Lesniak
Deferoxamine for aluminum toxicity in dialysis patients.
June 1990, ANNA journal,
M Lewis, and S Lesniak
Treatment of aluminum toxicity in infantile uremia with deferoxamine.
July 1986, The Journal of pediatrics,
M Lewis, and S Lesniak
Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
December 1986, Seminars in nephrology,
M Lewis, and S Lesniak
[Aluminum accumulation and deferoxamine].
July 1993, Deutsche medizinische Wochenschrift (1946),
M Lewis, and S Lesniak
Deferoxamine and aluminum removal.
November 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation,
M Lewis, and S Lesniak
Iliac crest bone biopsy for diagnosis of aluminum toxicity and a guide to the use of deferoxamine.
December 1986, Seminars in nephrology,
M Lewis, and S Lesniak
Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine.
July 1992, Clinical pharmacy,
M Lewis, and S Lesniak
Citric, malic and succinic acids as possible alternatives to deferoxamine in aluminum toxicity.
January 1988, Journal of toxicology. Clinical toxicology,
M Lewis, and S Lesniak
Aluminum and deferoxamine kinetics in CAPD.
January 1991, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis,
M Lewis, and S Lesniak
Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis.
March 2000, Journal of clinical pharmacology,
Copied contents to your clipboard!